Login / Signup

The "RCT augmentation": a novel simulation method to add patient heterogeneity into phase III trials.

Helene KarcherShuai FuJie MengMikkel Zöllner AnkarfeldtOrestis EfthimiouMark BelgerJosep Maria HaroLucien AbenhaimClementine Nordonnull null
Published in: BMC medical research methodology (2018)
Simulating the inclusion of real-world subpopulations into an RCT before running it allows for quantification of the impact of each re-inclusion upon effect detection (statistical power) and generalizability of trial results, thereby explicating this trade-off and enabling a controlled increase in population heterogeneity in the RCT design.
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • single cell
  • phase ii
  • double blind
  • placebo controlled
  • case report
  • study protocol
  • high intensity
  • soft tissue
  • label free